Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5611 | ML 348 |
| Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). Exhibits 14-fold selectivity for LYPLA1 over LYPLA2. Also selective over a panel of ~30 other serine hydrolases. | |
| BCC5612 | ML 349 |
| Selective and reversible lysophospholipase 2 (LYPLA2) inhibitor (IC50 = 144 nM). Displays selectively over LYPLA1 and 20 other serine hydrolases (IC50 values are >3000 and >10,000 nM respectively). | |
| BCC5614 | CKI 7 dihydrochloride |
| Casein kinase 1 (CK1) inhibitor. Also inhibits SGK, S6K1 and MSK1. Induces retinal cell differentiation from human ESCs and iPSCs in combination with SB 431542 and Y-27632. | |
| BCC5616 | 3PO |
| Originally reported to inhibit PFKFB3 (IC50 = 25 μM). More recent reports failed to demonstrate activity in a PFKFB3 kinase assay. Reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade. | |
| BCC5617 | T 5601640 |
| Selective LIM kinase 2 (LIMK2) inhibitor; inhibits cofilin phosphorylation in cells that overexpress LIMK2 but not LIMK1. Attenuates the growth of several cancer cell lines. Reduces phospho-cofilin levels and Panc-1 tumor size in a mouse xenograft model. | |
| BCC5618 | UNC 3230 |
| Potent and selective PIP5K1C inhibitor (IC50 = 41 nM). Exhibits selectivity for PIP5K1C over PIP5K1A, the PI 3-kinase family and a panel of other kinases. Reduces PIP2 levels and LPA-induced calcium signaling in dorsal root ganglia (DRG) neurons in vitro. Reduces nociception in mouse models of chronic pain. | |
| BCC5619 | Bryostatin 2 |
| Protein kinase C (PKC) activator; analog of Bryostatin 1. Attenuates cell proliferation and cell attachment in U937 cells. Inhibits DNA synthesis at 100 nM in SH-SY5Y human neuroblastoma cells. Also inhibits EGF binding and induces arachidonic acid release in vitro. Antitumor. | |
| BCC5620 | Bryostatin 3 |
| Potent protein kinase C activator (KI = 2.75 nM). Attenuates phorbol 12-myristate 13-acetate inhibition of GH4C1 pituitary cell proliferation in vitro. | |
